{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:51:39Z","timestamp":1775148699569,"version":"3.50.1"},"reference-count":98,"publisher":"American Spinal Injury Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Individuals with spinal cord injuries (SCI) experience depression at rates up to 5 times higher than the general population. Although research on hallucinogens for treating depression is growing, no studies have specifically focused on individuals with SCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To identify factors associated with hallucinogen use and explore the relationship between hallucinogen use and psychosocial outcomes (i.e., depression and quality of life [QOL]) among individuals with SCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This exploratory, retrospective cross-sectional study design used data from 9976 participants in the Spinal Cord Injury Model Systems (SCIMS) National Database (NDB) between 2016 and 2021. The study outcomes were depression (Patient Health Questionnaire\u20139 [PHQ-9]) and QOL (Satisfaction with Life Scale [SWLS]). Hallucinogen use, measured by the WHO ASSIST 2, was dichotomized into some use versus no use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Overall, 65 participants (0.7%) reported some hallucinogen use in the prior 3 months. Multivariable logistic regression analysis showed that younger age, male sex, fall(s) in the previous year, and sleep disturbances were all associated with hallucinogen use. In multivariable linear regression, hallucinogen use was significantly associated with higher PHQ-9 scores (effect size [ES] 0.558) but was not significantly related to SWLS scores (ES 0.149).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This is the first study to identify demographic, injury, and psychosocial factors associated with hallucinogen use among individuals with SCI and to explore its relation to depression and QOL. These findings provide a foundation for future, fully powered studies aimed at determining the effect of hallucinogen use in the SCI population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.46292\/sci24-00082","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T16:36:52Z","timestamp":1763483812000},"page":"160-174","source":"Crossref","is-referenced-by-count":0,"title":["Association of Hallucinogen Use With Psychosocial Outcomes: Secondary Analysis of the Spinal Cord Injury Model Systems Database"],"prefix":"10.46292","volume":"31","author":[{"given":"Kayleigh","family":"Crane","sequence":"first","affiliation":[{"name":"College of Medicine, Central Michigan University, Mount Pleasant, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Hanks Philippus","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, University of Minnesota Medical School, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Coker","sequence":"additional","affiliation":[{"name":"Research Department, Craig Hospital, Englewood, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse L.","family":"Kowalski","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, University of Minnesota Medical School, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley R.","family":"Monden","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, University of Minnesota Medical School, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"25425","reference":[{"issue":"2","key":"b1","series-title":"Neuroepidemiology","first-page":"55","article-title":"Depression following traumatic spinal cord injury","volume":"25","author":"Dryden DM","year":"2005","unstructured":"Dryden DM, Saunders LD, Rowe BH, et al. Depression following traumatic spinal cord injury. Neuroepidemiology. 2005;25(2):55-61."},{"issue":"10","key":"b2","series-title":"Intern Med J","first-page":"1014","article-title":"Prevalence of mood disturbance in Australian adults with chronic spinal cord injury: Spinal cord injury and mental health","volume":"45","author":"Migliorini C","year":"2015","unstructured":"Migliorini C, Sinclair A, Brown D, Tonge B, New P. Prevalence of mood disturbance in Australian adults with chronic spinal cord injury: Spinal cord injury and mental health. Intern Med J. 2015;45(10):1014-1019."},{"issue":"8","key":"b3","series-title":"Life","article-title":"The potential role of serotonergic hallucinogens in depression treatment","volume":"11","author":"Psiuk D","year":"2021","unstructured":"Psiuk D, Nowak E, Cholewa K, \u0141opusza\u0144ska U, Samardakiewicz M. The potential role of serotonergic hallucinogens in depression treatment. Life. 2021;11(8). doi:10.3390\/life11080765."},{"issue":"12","key":"b4","series-title":"J Psychopharmacol","first-page":"1181","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths RR","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197."},{"key":"b5","series-title":"Psychological Aspects of Cancer","first-page":"291","article-title":"Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer","author":"Grob CS","year":"2013","unstructured":"Grob CS, Bossis AP, Griffiths RR. Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer. In: Psychological Aspects of Cancer. Springer; 2013:291-308."},{"issue":"115886","key":"b6","series-title":"Psychiatry Res","first-page":"115886","article-title":"Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis","volume":"335","author":"Yao Y","year":"2024","unstructured":"Yao Y, Guo D, Lu TS, et al. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;335(115886):115886."},{"issue":"7","key":"b7","series-title":"Lancet Psychiatry","first-page":"619","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Carhart-Harris RL","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-627."},{"issue":"5","key":"b8","series-title":"JAMA Psychiatry","first-page":"481","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial","volume":"78","author":"Davis AK","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry. 2021;78(5):481-489."},{"issue":"11","key":"b9","series-title":"Spinal Cord","first-page":"973","article-title":"Pain, spasticity and quality of life in individuals with traumatic spinal cord injury in Denmark","volume":"54","author":"Andresen SR","year":"2016","unstructured":"Andresen SR, Biering-S\u00f8rensen F, Hagen EM, Nielsen JF, Bach FW, Finnerup NB. Pain, spasticity and quality of life in individuals with traumatic spinal cord injury in Denmark. Spinal Cord. 2016;54(11):973-979."},{"issue":"12","key":"b10","series-title":"Spinal Cord","first-page":"1046","article-title":"Neuropathic pain and spasticity: intricate consequences of spinal cord injury","volume":"55","author":"Finnerup NB","year":"2017","unstructured":"Finnerup NB. Neuropathic pain and spasticity: intricate consequences of spinal cord injury. Spinal Cord. 2017;55(12):1046-1050."},{"key":"b11","series-title":"DEA","author":"Drug Scheduling","unstructured":"Drug Scheduling. DEA. Accessed June 14, 2024. https:\/\/www.dea.gov\/drug-information\/drug-scheduling."},{"issue":"4","key":"b12","series-title":"JAMA","first-page":"307","article-title":"FDA proposes first guidance for researchers studying psychedelics","volume":"330","author":"Harris E","year":"2023","unstructured":"Harris E. FDA proposes first guidance for researchers studying psychedelics. JAMA. 2023;330(4):307."},{"issue":"4","key":"b13","series-title":"Pain","first-page":"698","article-title":"Microdosing psilocybin for chronic pain: A case series","volume":"164","author":"Lyes M","year":"2023","unstructured":"Lyes M, Yang KH, Castellanos J, Furnish T. Microdosing psilocybin for chronic pain: A case series. Pain. 2023;164(4):698-702."},{"issue":"4","key":"b14","series-title":"Anesthesiology","first-page":"523","article-title":"Use of psychedelics for pain: A scoping review","volume":"139","author":"Goel A","year":"2023","unstructured":"Goel A, Rai Y, Sivadas S, et al. Use of psychedelics for pain: A scoping review. Anesthesiology. 2023;139(4):523-536."},{"key":"b15","series-title":"Pharmacol Ther","first-page":"83","article-title":"Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson MW","year":"2019","unstructured":"Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019;197:83-102."},{"issue":"17","key":"b16","series-title":"Br J Pharmacol","first-page":"4254","article-title":"Ketamine and phencyclidine: The good, the bad and the unexpected","volume":"172","author":"Lodge D","year":"2015","unstructured":"Lodge D, Mercier MS. Ketamine and phencyclidine: The good, the bad and the unexpected. Br J Pharmacol. 2015;172(17):4254-4276."},{"key":"b17","article-title":"Psychedelic and Dissociative Drugs","author":"National Institute on Drug Abuse","unstructured":"National Institute on Drug Abuse. Psychedelic and Dissociative Drugs. National Institute on Drug Abuse. Accessed June 14, 2024. https:\/\/nida.nih.gov\/research-topics\/psychedelic-dissociative-drugs."},{"issue":"11","key":"b18","series-title":"Cell Rep","first-page":"3170","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly C","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23(11):3170-3182."},{"issue":"6","key":"b19","series-title":"Cell","first-page":"1574","article-title":"Structure of a hallucinogen-activated gq-coupled 5-HT2A serotonin receptor","volume":"182","author":"Kim K","year":"2020","unstructured":"Kim K, Che T, Panova O, et al. Structure of a hallucinogen-activated gq-coupled 5-HT2A serotonin receptor. Cell. 2020;182(6):1574-1588.e19."},{"issue":"4","key":"b20","series-title":"Int J Mol Sci","first-page":"1927","article-title":"The role of central serotonin neurons and 5-HT heteroreceptor complexes in the pathophysiology of depression: A historical perspective and future prospects","volume":"22","author":"Borroto-Escuela DO","year":"2021","unstructured":"Borroto-Escuela DO, Ambrogini P, Chru\u015bcicka B, et al. The role of central serotonin neurons and 5-HT heteroreceptor complexes in the pathophysiology of depression: A historical perspective and future prospects. Int J Mol Sci. 2021;22(4):1927."},{"key":"b21","series-title":"Recovery of Motor Function Following Spinal Cord Injury","article-title":"Normal distribution and plasticity of serotonin receptors after spinal cord injury and their impacts on motor outputs","author":"Zhang M","year":"2016","unstructured":"Zhang M. Normal distribution and plasticity of serotonin receptors after spinal cord injury and their impacts on motor outputs. In: Recovery of Motor Function Following Spinal Cord Injury. InTech; 2016."},{"issue":"1","key":"b22","series-title":"Neurotrauma Rep","first-page":"543","article-title":"Persons with spinal cord injury report peripherally dominant serotonin-like syndrome after use of serotonergic psychedelics","volume":"4","author":"Abrams SK","year":"2023","unstructured":"Abrams SK, Rabinovitch BS, Zafar R, et al. Persons with spinal cord injury report peripherally dominant serotonin-like syndrome after use of serotonergic psychedelics. Neurotrauma Rep. 2023;4(1):543-550."},{"issue":"1-3","key":"b23","series-title":"Eur J Pharmacol","first-page":"8","article-title":"Multiple roles of serotonin in pain control mechanisms--implications of 5-HT\u0144 and other 5-HT receptor types","volume":"716","author":"Viguier F","year":"2013","unstructured":"Viguier F, Michot B, Hamon M, Bourgoin S. Multiple roles of serotonin in pain control mechanisms--implications of 5-HT\u0144 and other 5-HT receptor types. Eur J Pharmacol. 2013;716(1-3):8-16."},{"key":"b24","series-title":"Front Psychiatry","first-page":"914458","article-title":"Physical disability and psychedelic therapies: An agenda for inclusive research and practice","volume":"13","author":"Mintz KT","year":"2022","unstructured":"Mintz KT, Gammer B, Khan AJ, Shaub G, Levine S, Sisti D. Physical disability and psychedelic therapies: An agenda for inclusive research and practice. Front Psychiatry. 2022;13:914458."},{"issue":"9","key":"b25","series-title":"Psychiatr Ann","first-page":"509","article-title":"The PHQ-9: A new depression diagnostic and severity measure","volume":"32","author":"Kroenke K","year":"2002","unstructured":"Kroenke K, Spitzer RL. The PHQ-9: A new depression diagnostic and severity measure. Psychiatr Ann. 2002;32(9):509-515."},{"issue":"1","key":"b26","series-title":"J Pers Assess","first-page":"71","article-title":"The Satisfaction With Life Scale","volume":"49","author":"Diener E","year":"1985","unstructured":"Diener E, Emmons RA, Larsen RJ, Griffin S. The Satisfaction With Life Scale. J Pers Assess. 1985;49(1):71-75."},{"key":"b27","author":"The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)","year":"2010","unstructured":"The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). January 1, 2010. Accessed November 4, 2024. https:\/\/www.who.int\/publications\/i\/item\/978924159938-2."},{"key":"b28","series-title":"Manual and interpretation guide 2","article-title":"SF-36 health survey","author":"Ware JE","year":"1993","unstructured":"Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey.\u201d Manual and interpretation guide 2. Published online 1993. https:\/\/www.researchgate.net\/profile\/John-Ware-6\/publication\/313050850_SF-36_Health_Survey_Manual_Interpretation_Guide\/links\/594a5ac4a6fdcc89090c9cef\/SF-36-Health-Survey-Manual-Interpretation-Guide.pdf."},{"key":"b29","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen J","year":"1998","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Lawrence Erlbaum Associates; 1998."},{"issue":"3","key":"b30","series-title":"Neuron","first-page":"439","article-title":"Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonz\u00e1lez-Maeso J","year":"2007","unstructured":"Gonz\u00e1lez-Maeso J, Weisstaub NV, Zhou M, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53(3):439-452."},{"key":"b31","series-title":"Considering Alternatives to Psychedelic Drug Prohibition","author":"Kilmer B","year":"2024","unstructured":"Kilmer B, Priest M, Ramchand R, Rogers R, Senator B, Palmer K. Considering Alternatives to Psychedelic Drug Prohibition. RAND Corporation; 2024."},{"key":"b32","series-title":"F1000Res","first-page":"98","article-title":"Over 30 million psychedelic users in the United States","volume":"2","author":"Krebs TS","year":"2013","unstructured":"Krebs TS, Johansen P\u00d8. Over 30 million psychedelic users in the United States. F1000Res. 2013;2:98."},{"issue":"3","key":"b33","series-title":"Drug Alcohol Depend","first-page":"143","article-title":"Age-specific patterns of hallucinogen use in the US population: An analysis using generalized additive models","volume":"43","author":"Chilcoat HD","year":"1996","unstructured":"Chilcoat HD, Sch\u00fctz CG. Age-specific patterns of hallucinogen use in the US population: An analysis using generalized additive models. Drug Alcohol Depend. 1996;43(3):143-153."},{"issue":"12","key":"b34","series-title":"Addiction","first-page":"3099","article-title":"Adolescent and adult time trends in US hallucinogen use, 2002-19: Any use, and use of ecstasy, LSD and PCP","volume":"117","author":"Livne O","year":"2022","unstructured":"Livne O, Shmulewitz D, Walsh C, Hasin DS. Adolescent and adult time trends in US hallucinogen use, 2002-19: Any use, and use of ecstasy, LSD and PCP. Addiction. 2022;117(12):3099-3109."},{"key":"b35","series-title":"Front Epidemiol","first-page":"876706","article-title":"Race, ethnic, and sex differences in prevalence of and trends in hallucinogen consumption among lifetime users in the United States between 2015 and 2019","volume":"2","author":"Davis AK","year":"2022","unstructured":"Davis AK, Arterberry BJ, Xin Y, Agin-Liebes G, Schwarting C, Williams MT. Race, ethnic, and sex differences in prevalence of and trends in hallucinogen consumption among lifetime users in the United States between 2015 and 2019. Front Epidemiol. 2022;2:876706."},{"issue":"2","key":"b36","series-title":"Drug Alcohol Depend","first-page":"117","article-title":"Comparative epidemiology of initial drug opportunities and transitions to first use: Marijuana, cocaine, hallucinogens and heroin","volume":"54","author":"Etten ML","year":"1999","unstructured":"Van Etten ML, Anthony JC. Comparative epidemiology of initial drug opportunities and transitions to first use: Marijuana, cocaine, hallucinogens and heroin. Drug Alcohol Depend. 1999;54(2):117-125."},{"issue":"1","key":"b37","series-title":"Evol Psychol","first-page":"29","article-title":"Sex differences in everyday risk-taking behavior in humans","volume":"6","author":"Pawlowski B","year":"2008","unstructured":"Pawlowski B, Atwal R, Dunbar RIM. Sex differences in everyday risk-taking behavior in humans. Evol Psychol. 2008;6(1):29-42."},{"issue":"1","key":"b38","series-title":"Clin Geriatr Med","first-page":"55","article-title":"Hallucinogen use and misuse in older adults","volume":"38","author":"Redden WM","year":"2022","unstructured":"Redden WM, Paracha SUR, Sheheryar Q. Hallucinogen use and misuse in older adults. Clin Geriatr Med. 2022;38(1):55-66."},{"key":"b39","series-title":"Front Pharmacol","first-page":"602590","article-title":"The effects of daytime psilocybin administration on sleep: Implications for antidepressant action","volume":"11","author":"Dudysov\u00e1 D","year":"2020","unstructured":"Dudysov\u00e1 D, Jank\u015b K, \u0160motek M, et al. The effects of daytime psilocybin administration on sleep: Implications for antidepressant action. Front Pharmacol. 2020;11:602590."},{"key":"b40","series-title":"Front Psychiatry","first-page":"955626","article-title":"Illegal drug use is associated with poorer life satisfaction and self-rated health (SRH) in young people","volume":"14","author":"Kang W","year":"2023","unstructured":"Kang W. Illegal drug use is associated with poorer life satisfaction and self-rated health (SRH) in young people. Front Psychiatry. 2023;14:955626."},{"issue":"107343","key":"b41","series-title":"Addict Behav","first-page":"107343","article-title":"Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults","volume":"132","author":"Yang KH","year":"2022","unstructured":"Yang KH, Han BH, Palamar JJ. Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults. Addict Behav. 2022;132(107343):107343."},{"issue":"3","key":"b42","series-title":"J Psychopharmacol","first-page":"258","article-title":"Adverse effects of psychedelics: From anecdotes and misinformation to systematic science","volume":"36","author":"Schlag AK","year":"2022","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J Psychopharmacol. 2022;36(3):258-272."},{"issue":"11","key":"b43","series-title":"J Psychopharmacol","first-page":"1434","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies","volume":"25","author":"Studerus E","year":"2011","unstructured":"Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. J Psychopharmacol. 2011;25(11):1434-1452."},{"issue":"10","key":"b44","series-title":"PLoS One","article-title":"Extended difficulties following the use of psychedelic drugs: A mixed methods study","volume":"18","author":"Evans J","year":"2023","unstructured":"Evans J, Robinson OC, Argyri EK, et al. Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLoS One. 2023;18(10):e0293349."},{"key":"b45","series-title":"Psychopharmacology (Berl)","article-title":"Psychedelic use and psychiatric risks [published online October 24, 2023]","author":"Simonsson O","unstructured":"Simonsson O, Goldberg SB, Chambers R, Osika W, Simonsson C, Hendricks PS. Psychedelic use and psychiatric risks [published online October 24, 2023]. Psychopharmacology (Berl)."},{"issue":"4","key":"b46","series-title":"Arch Phys Med Rehabil","first-page":"747","article-title":"Mediating effects of pain interference on the relationships between pain intensity and probable major depression among participants with spinal cord injury","volume":"103","author":"Li C","year":"2022","unstructured":"Li C, DiPiro ND, Clark JMR, Krause JS. Mediating effects of pain interference on the relationships between pain intensity and probable major depression among participants with spinal cord injury. Arch Phys Med Rehabil. 2022;103(4):747-754."},{"issue":"4","key":"b47","series-title":"Psychiatr Clin North Am","first-page":"1009","article-title":"Sleep in mood disorders","volume":"29","author":"Peterson MJ","year":"2006","unstructured":"Peterson MJ, Benca RM. Sleep in mood disorders. Psychiatr Clin North Am. 2006;29(4):1009-1032; abstract ix."},{"issue":"8","key":"b48","series-title":"Cureus","article-title":"Chronic pain-induced depression: A review of prevalence and management","volume":"14","author":"Meda RT","year":"2022","unstructured":"Meda RT, Nuguru SP, Rachakonda S, Sripathi S, Khan MI, Patel N. Chronic pain-induced depression: A review of prevalence and management. Cureus. 2022;14(8):e28416."},{"issue":"1","key":"b49","series-title":"JAMA Psychiatry","first-page":"77","article-title":"Psychedelic drug legislative reform and legalization in the US","volume":"80","author":"Siegel JS","year":"2023","unstructured":"Siegel JS, Daily JE, Perry DA, Nicol GE. Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry. 2023;80(1):77-83."},{"issue":"2","key":"b1","series-title":"Neuroepidemiology","first-page":"55","article-title":"Depression following traumatic spinal cord injury","volume":"25","author":"Dryden DM","year":"2005","unstructured":"Dryden DM, Saunders LD, Rowe BH, et al. Depression following traumatic spinal cord injury. Neuroepidemiology. 2005;25(2):55-61."},{"issue":"10","key":"b2","series-title":"Intern Med J","first-page":"1014","article-title":"Prevalence of mood disturbance in Australian adults with chronic spinal cord injury: Spinal cord injury and mental health","volume":"45","author":"Migliorini C","year":"2015","unstructured":"Migliorini C, Sinclair A, Brown D, Tonge B, New P. Prevalence of mood disturbance in Australian adults with chronic spinal cord injury: Spinal cord injury and mental health. Intern Med J. 2015;45(10):1014-1019."},{"issue":"8","key":"b3","series-title":"Life","article-title":"The potential role of serotonergic hallucinogens in depression treatment","volume":"11","author":"Psiuk D","year":"2021","unstructured":"Psiuk D, Nowak E, Cholewa K, \u0141opusza\u0144ska U, Samardakiewicz M. The potential role of serotonergic hallucinogens in depression treatment. Life. 2021;11(8). doi:10.3390\/life11080765."},{"issue":"12","key":"b4","series-title":"J Psychopharmacol","first-page":"1181","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths RR","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197."},{"key":"b5","series-title":"Psychological Aspects of Cancer","first-page":"291","article-title":"Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer","author":"Grob CS","year":"2013","unstructured":"Grob CS, Bossis AP, Griffiths RR. Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer. In: Psychological Aspects of Cancer. Springer; 2013:291-308."},{"issue":"115886","key":"b6","series-title":"Psychiatry Res","first-page":"115886","article-title":"Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis","volume":"335","author":"Yao Y","year":"2024","unstructured":"Yao Y, Guo D, Lu TS, et al. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;335(115886):115886."},{"issue":"7","key":"b7","series-title":"Lancet Psychiatry","first-page":"619","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Carhart-Harris RL","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-627."},{"issue":"5","key":"b8","series-title":"JAMA Psychiatry","first-page":"481","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial","volume":"78","author":"Davis AK","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry. 2021;78(5):481-489."},{"issue":"11","key":"b9","series-title":"Spinal Cord","first-page":"973","article-title":"Pain, spasticity and quality of life in individuals with traumatic spinal cord injury in Denmark","volume":"54","author":"Andresen SR","year":"2016","unstructured":"Andresen SR, Biering-S\u00f8rensen F, Hagen EM, Nielsen JF, Bach FW, Finnerup NB. Pain, spasticity and quality of life in individuals with traumatic spinal cord injury in Denmark. Spinal Cord. 2016;54(11):973-979."},{"issue":"12","key":"b10","series-title":"Spinal Cord","first-page":"1046","article-title":"Neuropathic pain and spasticity: intricate consequences of spinal cord injury","volume":"55","author":"Finnerup NB","year":"2017","unstructured":"Finnerup NB. Neuropathic pain and spasticity: intricate consequences of spinal cord injury. Spinal Cord. 2017;55(12):1046-1050."},{"key":"b11","series-title":"DEA","author":"Drug Scheduling","unstructured":"Drug Scheduling. DEA. Accessed June 14, 2024. https:\/\/www.dea.gov\/drug-information\/drug-scheduling."},{"issue":"4","key":"b12","series-title":"JAMA","first-page":"307","article-title":"FDA proposes first guidance for researchers studying psychedelics","volume":"330","author":"Harris E","year":"2023","unstructured":"Harris E. FDA proposes first guidance for researchers studying psychedelics. JAMA. 2023;330(4):307."},{"issue":"4","key":"b13","series-title":"Pain","first-page":"698","article-title":"Microdosing psilocybin for chronic pain: A case series","volume":"164","author":"Lyes M","year":"2023","unstructured":"Lyes M, Yang KH, Castellanos J, Furnish T. Microdosing psilocybin for chronic pain: A case series. Pain. 2023;164(4):698-702."},{"issue":"4","key":"b14","series-title":"Anesthesiology","first-page":"523","article-title":"Use of psychedelics for pain: A scoping review","volume":"139","author":"Goel A","year":"2023","unstructured":"Goel A, Rai Y, Sivadas S, et al. Use of psychedelics for pain: A scoping review. Anesthesiology. 2023;139(4):523-536."},{"key":"b15","series-title":"Pharmacol Ther","first-page":"83","article-title":"Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson MW","year":"2019","unstructured":"Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019;197:83-102."},{"issue":"17","key":"b16","series-title":"Br J Pharmacol","first-page":"4254","article-title":"Ketamine and phencyclidine: The good, the bad and the unexpected","volume":"172","author":"Lodge D","year":"2015","unstructured":"Lodge D, Mercier MS. Ketamine and phencyclidine: The good, the bad and the unexpected. Br J Pharmacol. 2015;172(17):4254-4276."},{"key":"b17","article-title":"Psychedelic and Dissociative Drugs","author":"National Institute on Drug Abuse","unstructured":"National Institute on Drug Abuse. Psychedelic and Dissociative Drugs. National Institute on Drug Abuse. Accessed June 14, 2024. https:\/\/nida.nih.gov\/research-topics\/psychedelic-dissociative-drugs."},{"issue":"11","key":"b18","series-title":"Cell Rep","first-page":"3170","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly C","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23(11):3170-3182."},{"issue":"6","key":"b19","series-title":"Cell","first-page":"1574","article-title":"Structure of a hallucinogen-activated gq-coupled 5-HT2A serotonin receptor","volume":"182","author":"Kim K","year":"2020","unstructured":"Kim K, Che T, Panova O, et al. Structure of a hallucinogen-activated gq-coupled 5-HT2A serotonin receptor. Cell. 2020;182(6):1574-1588.e19."},{"issue":"4","key":"b20","series-title":"Int J Mol Sci","first-page":"1927","article-title":"The role of central serotonin neurons and 5-HT heteroreceptor complexes in the pathophysiology of depression: A historical perspective and future prospects","volume":"22","author":"Borroto-Escuela DO","year":"2021","unstructured":"Borroto-Escuela DO, Ambrogini P, Chru\u015bcicka B, et al. The role of central serotonin neurons and 5-HT heteroreceptor complexes in the pathophysiology of depression: A historical perspective and future prospects. Int J Mol Sci. 2021;22(4):1927."},{"key":"b21","series-title":"Recovery of Motor Function Following Spinal Cord Injury","article-title":"Normal distribution and plasticity of serotonin receptors after spinal cord injury and their impacts on motor outputs","author":"Zhang M","year":"2016","unstructured":"Zhang M. Normal distribution and plasticity of serotonin receptors after spinal cord injury and their impacts on motor outputs. In: Recovery of Motor Function Following Spinal Cord Injury. InTech; 2016."},{"issue":"1","key":"b22","series-title":"Neurotrauma Rep","first-page":"543","article-title":"Persons with spinal cord injury report peripherally dominant serotonin-like syndrome after use of serotonergic psychedelics","volume":"4","author":"Abrams SK","year":"2023","unstructured":"Abrams SK, Rabinovitch BS, Zafar R, et al. Persons with spinal cord injury report peripherally dominant serotonin-like syndrome after use of serotonergic psychedelics. Neurotrauma Rep. 2023;4(1):543-550."},{"issue":"1-3","key":"b23","series-title":"Eur J Pharmacol","first-page":"8","article-title":"Multiple roles of serotonin in pain control mechanisms--implications of 5-HT\u0144 and other 5-HT receptor types","volume":"716","author":"Viguier F","year":"2013","unstructured":"Viguier F, Michot B, Hamon M, Bourgoin S. Multiple roles of serotonin in pain control mechanisms--implications of 5-HT\u0144 and other 5-HT receptor types. Eur J Pharmacol. 2013;716(1-3):8-16."},{"key":"b24","series-title":"Front Psychiatry","first-page":"914458","article-title":"Physical disability and psychedelic therapies: An agenda for inclusive research and practice","volume":"13","author":"Mintz KT","year":"2022","unstructured":"Mintz KT, Gammer B, Khan AJ, Shaub G, Levine S, Sisti D. Physical disability and psychedelic therapies: An agenda for inclusive research and practice. Front Psychiatry. 2022;13:914458."},{"issue":"9","key":"b25","series-title":"Psychiatr Ann","first-page":"509","article-title":"The PHQ-9: A new depression diagnostic and severity measure","volume":"32","author":"Kroenke K","year":"2002","unstructured":"Kroenke K, Spitzer RL. The PHQ-9: A new depression diagnostic and severity measure. Psychiatr Ann. 2002;32(9):509-515."},{"issue":"1","key":"b26","series-title":"J Pers Assess","first-page":"71","article-title":"The Satisfaction With Life Scale","volume":"49","author":"Diener E","year":"1985","unstructured":"Diener E, Emmons RA, Larsen RJ, Griffin S. The Satisfaction With Life Scale. J Pers Assess. 1985;49(1):71-75."},{"key":"b27","author":"The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)","year":"2010","unstructured":"The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). January 1, 2010. Accessed November 4, 2024. https:\/\/www.who.int\/publications\/i\/item\/978924159938-2."},{"key":"b28","series-title":"Manual and interpretation guide 2","article-title":"SF-36 health survey","author":"Ware JE","year":"1993","unstructured":"Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey.\u201d Manual and interpretation guide 2. Published online 1993. https:\/\/www.researchgate.net\/profile\/John-Ware-6\/publication\/313050850_SF-36_Health_Survey_Manual_Interpretation_Guide\/links\/594a5ac4a6fdcc89090c9cef\/SF-36-Health-Survey-Manual-Interpretation-Guide.pdf."},{"key":"b29","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen J","year":"1998","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Lawrence Erlbaum Associates; 1998."},{"issue":"3","key":"b30","series-title":"Neuron","first-page":"439","article-title":"Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonz\u00e1lez-Maeso J","year":"2007","unstructured":"Gonz\u00e1lez-Maeso J, Weisstaub NV, Zhou M, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53(3):439-452."},{"key":"b31","series-title":"Considering Alternatives to Psychedelic Drug Prohibition","author":"Kilmer B","year":"2024","unstructured":"Kilmer B, Priest M, Ramchand R, Rogers R, Senator B, Palmer K. Considering Alternatives to Psychedelic Drug Prohibition. RAND Corporation; 2024."},{"key":"b32","series-title":"F1000Res","first-page":"98","article-title":"Over 30 million psychedelic users in the United States","volume":"2","author":"Krebs TS","year":"2013","unstructured":"Krebs TS, Johansen P\u00d8. Over 30 million psychedelic users in the United States. F1000Res. 2013;2:98."},{"issue":"3","key":"b33","series-title":"Drug Alcohol Depend","first-page":"143","article-title":"Age-specific patterns of hallucinogen use in the US population: An analysis using generalized additive models","volume":"43","author":"Chilcoat HD","year":"1996","unstructured":"Chilcoat HD, Sch\u00fctz CG. Age-specific patterns of hallucinogen use in the US population: An analysis using generalized additive models. Drug Alcohol Depend. 1996;43(3):143-153."},{"issue":"12","key":"b34","series-title":"Addiction","first-page":"3099","article-title":"Adolescent and adult time trends in US hallucinogen use, 2002-19: Any use, and use of ecstasy, LSD and PCP","volume":"117","author":"Livne O","year":"2022","unstructured":"Livne O, Shmulewitz D, Walsh C, Hasin DS. Adolescent and adult time trends in US hallucinogen use, 2002-19: Any use, and use of ecstasy, LSD and PCP. Addiction. 2022;117(12):3099-3109."},{"key":"b35","series-title":"Front Epidemiol","first-page":"876706","article-title":"Race, ethnic, and sex differences in prevalence of and trends in hallucinogen consumption among lifetime users in the United States between 2015 and 2019","volume":"2","author":"Davis AK","year":"2022","unstructured":"Davis AK, Arterberry BJ, Xin Y, Agin-Liebes G, Schwarting C, Williams MT. Race, ethnic, and sex differences in prevalence of and trends in hallucinogen consumption among lifetime users in the United States between 2015 and 2019. Front Epidemiol. 2022;2:876706."},{"issue":"2","key":"b36","series-title":"Drug Alcohol Depend","first-page":"117","article-title":"Comparative epidemiology of initial drug opportunities and transitions to first use: Marijuana, cocaine, hallucinogens and heroin","volume":"54","author":"Etten ML","year":"1999","unstructured":"Van Etten ML, Anthony JC. Comparative epidemiology of initial drug opportunities and transitions to first use: Marijuana, cocaine, hallucinogens and heroin. Drug Alcohol Depend. 1999;54(2):117-125."},{"issue":"1","key":"b37","series-title":"Evol Psychol","first-page":"29","article-title":"Sex differences in everyday risk-taking behavior in humans","volume":"6","author":"Pawlowski B","year":"2008","unstructured":"Pawlowski B, Atwal R, Dunbar RIM. Sex differences in everyday risk-taking behavior in humans. Evol Psychol. 2008;6(1):29-42."},{"issue":"1","key":"b38","series-title":"Clin Geriatr Med","first-page":"55","article-title":"Hallucinogen use and misuse in older adults","volume":"38","author":"Redden WM","year":"2022","unstructured":"Redden WM, Paracha SUR, Sheheryar Q. Hallucinogen use and misuse in older adults. Clin Geriatr Med. 2022;38(1):55-66."},{"key":"b39","series-title":"Front Pharmacol","first-page":"602590","article-title":"The effects of daytime psilocybin administration on sleep: Implications for antidepressant action","volume":"11","author":"Dudysov\u00e1 D","year":"2020","unstructured":"Dudysov\u00e1 D, Jank\u015b K, \u0160motek M, et al. The effects of daytime psilocybin administration on sleep: Implications for antidepressant action. Front Pharmacol. 2020;11:602590."},{"key":"b40","series-title":"Front Psychiatry","first-page":"955626","article-title":"Illegal drug use is associated with poorer life satisfaction and self-rated health (SRH) in young people","volume":"14","author":"Kang W","year":"2023","unstructured":"Kang W. Illegal drug use is associated with poorer life satisfaction and self-rated health (SRH) in young people. Front Psychiatry. 2023;14:955626."},{"issue":"107343","key":"b41","series-title":"Addict Behav","first-page":"107343","article-title":"Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults","volume":"132","author":"Yang KH","year":"2022","unstructured":"Yang KH, Han BH, Palamar JJ. Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults. Addict Behav. 2022;132(107343):107343."},{"issue":"3","key":"b42","series-title":"J Psychopharmacol","first-page":"258","article-title":"Adverse effects of psychedelics: From anecdotes and misinformation to systematic science","volume":"36","author":"Schlag AK","year":"2022","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J Psychopharmacol. 2022;36(3):258-272."},{"issue":"11","key":"b43","series-title":"J Psychopharmacol","first-page":"1434","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies","volume":"25","author":"Studerus E","year":"2011","unstructured":"Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. J Psychopharmacol. 2011;25(11):1434-1452."},{"issue":"10","key":"b44","series-title":"PLoS One","article-title":"Extended difficulties following the use of psychedelic drugs: A mixed methods study","volume":"18","author":"Evans J","year":"2023","unstructured":"Evans J, Robinson OC, Argyri EK, et al. Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLoS One. 2023;18(10):e0293349."},{"key":"b45","series-title":"Psychopharmacology (Berl)","article-title":"Psychedelic use and psychiatric risks [published online October 24, 2023]","author":"Simonsson O","unstructured":"Simonsson O, Goldberg SB, Chambers R, Osika W, Simonsson C, Hendricks PS. Psychedelic use and psychiatric risks [published online October 24, 2023]. Psychopharmacology (Berl)."},{"issue":"4","key":"b46","series-title":"Arch Phys Med Rehabil","first-page":"747","article-title":"Mediating effects of pain interference on the relationships between pain intensity and probable major depression among participants with spinal cord injury","volume":"103","author":"Li C","year":"2022","unstructured":"Li C, DiPiro ND, Clark JMR, Krause JS. Mediating effects of pain interference on the relationships between pain intensity and probable major depression among participants with spinal cord injury. Arch Phys Med Rehabil. 2022;103(4):747-754."},{"issue":"4","key":"b47","series-title":"Psychiatr Clin North Am","first-page":"1009","article-title":"Sleep in mood disorders","volume":"29","author":"Peterson MJ","year":"2006","unstructured":"Peterson MJ, Benca RM. Sleep in mood disorders. Psychiatr Clin North Am. 2006;29(4):1009-1032; abstract ix."},{"issue":"8","key":"b48","series-title":"Cureus","article-title":"Chronic pain-induced depression: A review of prevalence and management","volume":"14","author":"Meda RT","year":"2022","unstructured":"Meda RT, Nuguru SP, Rachakonda S, Sripathi S, Khan MI, Patel N. Chronic pain-induced depression: A review of prevalence and management. Cureus. 2022;14(8):e28416."},{"issue":"1","key":"b49","series-title":"JAMA Psychiatry","first-page":"77","article-title":"Psychedelic drug legislative reform and legalization in the US","volume":"80","author":"Siegel JS","year":"2023","unstructured":"Siegel JS, Daily JE, Perry DA, Nicol GE. Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry. 2023;80(1):77-83."}],"container-title":["Topics in Spinal Cord Injury Rehabilitation"],"original-title":[],"link":[{"URL":"https:\/\/tscir.kglmeridian.com\/view\/journals\/tscr\/31\/4\/article-p160.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/tscir\/article-pdf\/31\/4\/160\/3549008\/i1945-5763-31-4-160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/tscir.kglmeridian.com\/downloadpdf\/journals\/tscr\/31\/4\/article-p160.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/tscir.kglmeridian.com\/downloadpdf\/journals\/tscr\/31\/4\/article-p160.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:51:01Z","timestamp":1775145061000},"score":1,"resource":{"primary":{"URL":"https:\/\/tscir.kglmeridian.com\/view\/journals\/tscr\/31\/4\/article-p160.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":98,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.46292\/sci24-00082","relation":{},"ISSN":["1082-0744","1945-5763"],"issn-type":[{"value":"1082-0744","type":"print"},{"value":"1945-5763","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}